| Literature DB >> 33674772 |
Yingwei Chen1, Eric A Toth2,3,4, Biao Ruan1, Eun Jung Choi1, Richard Simmerman1, Yihong Chen2, Yanan He2, Ruixue Wang2, Raquel Godoy-Ruiz2,4,5, Harlan King2,6, Gregory Custer2,7, D Travis Gallagher2,6, David A Rozak8, Melani Solomon2,7, Silvia Muro2,7,9, David J Weber2,3,4,5, John Orban10,11, Thomas R Fuerst12,13, Philip N Bryan14,15.
Abstract
We describe the design, kinetic properties, and structures of engineered subtilisin proteases that degrade the active form of RAS by cleaving a conserved sequence in switch 2. RAS is a signaling protein that, when mutated, drives a third of human cancers. To generate high specificity for the RAS target sequence, the active site was modified to be dependent on a cofactor (imidazole or nitrite) and protease sub-sites were engineered to create a linkage between substrate and cofactor binding. Selective proteolysis of active RAS arises from a 2-step process wherein sub-site interactions promote productive binding of the cofactor, enabling cleavage. Proteases engineered in this way specifically cleave active RAS in vitro, deplete the level of RAS in a bacterial reporter system, and also degrade RAS in human cell culture. Although these proteases target active RAS, the underlying design principles are fundamental and will be adaptable to many target proteins.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33674772 PMCID: PMC7935941 DOI: 10.1038/s42003-021-01818-7
Source DB: PubMed Journal: Commun Biol ISSN: 2399-3642